✦ LIBER ✦

370 A phase Ib study of escalating doses of Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitor Tivozanib and FOLFOX6 in patients with advanced gastrointestinal (GI) tumors

✍ Scribed by F. Eskens; C. Oldenhuis; P. Bhargava; W. Loos; B. Esteves; L. van Doorn; M. Cotreau; R. Dillon; J. Gietema; E. de Vries

Book ID: 119603053
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 45 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)72077-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I dose escalation study of epide

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

✍ Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Phase II study of SU5416—a small-molecul

Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

✍ Francis J. Giles; Maureen A. Cooper; Lewis Silverman; Judith E. Karp; Jeffrey E. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myeloid leukemia in blastic phase (CML

A Phase II Safety and Efficacy Study of

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

✍ Pili, Roberto; Qin, Rui; Flynn, P.J.; Picus, Joel; Millward, Michael; Ho, Wing M 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 791 KB

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB